UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 439

Sortiert nach

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Nature medicine, 2018-10, Vol.24 (10), p.1504-1506

2018

Volltextzugriff (PDF)

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

The New England journal of medicine, 2018-02, Vol.378 (5), p.439-448

2018

Volltextzugriff (PDF)

Can allogeneic haematopoietic cell transplantation be curative in classical Crohn's disease?

British journal of haematology, 2023-03, Vol.200 (5), p.541-542

2023

Volltextzugriff (PDF)

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

The New England journal of medicine, 2017-02, Vol.376 (6), p.536-547

2017

Volltextzugriff (PDF)

Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen

The Journal of immunology (1950), 2012-11, Vol.189 (10), p.5082-5088

2012

Volltextzugriff (PDF)

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Blood, 2014-06, Vol.123 (25), p.3855-3863

2014

Volltextzugriff (PDF)

One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

The New England journal of medicine, 2014-10, Vol.371 (18), p.1685-1694

2014

Volltextzugriff (PDF)

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

Blood, 2012-03, Vol.119 (11), p.2665-2674

2012

Volltextzugriff (PDF)

Clinical utility of natural killer cells in cancer therapy and transplantation

Seminars in immunology, 2014-04, Vol.26 (2), p.161-172

2014

Volltextzugriff (PDF)

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Cancer research (Chicago, Ill.), 2016-10, Vol.76 (19), p.5696-5706

2016

Volltextzugriff (PDF)

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Clinical cancer research, 2016-07, Vol.22 (14), p.3440-3450

2016

Volltextzugriff (PDF)

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Blood, 2014-05, Vol.123 (19), p.3016-3026

2014

Volltextzugriff (PDF)

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Blood, 2010-11, Vol.116 (22), p.4693-4699

2010

Volltextzugriff (PDF)

Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer

The cancer journal (Sudbury, Mass.), 2015-11, Vol.21 (6), p.486

2015

Volltextzugriff (PDF)

Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

Blood, 2016-02, Vol.127 (8), p.1044-1051

2016

Volltextzugriff (PDF)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002056

2021

Volltextzugriff (PDF)

The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT)

Immunological reviews, 2014-03, Vol.258 (1), p.45-63

2014

Volltextzugriff (PDF)

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

Blood, 2012-03, Vol.119 (13), p.3064-3072

2012

Volltextzugriff (PDF)

Therapeutic manipulation of innate lymphoid cells

JCI insight, 2021-03, Vol.6 (6)

2021

Volltextzugriff (PDF)

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units

Blood, 2009-11, Vol.114 (19), p.4293-4299

2009

Volltextzugriff (PDF)

Natural killer–cell differentiation by myeloid progenitors

Blood, 2011-03, Vol.117 (13), p.3548-3558

2011

Volltextzugriff (PDF)

Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity

Cancer Immunology, Immunotherapy : CII, 2024-03, Vol.73 (5), p.77-77, Article 77

2024

Volltextzugriff (PDF)

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Clinical cancer research, 2013-07, Vol.19 (14), p.3844-3855

2013

Volltextzugriff (PDF)

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

Clinical cancer research, 2013-07, Vol.19 (14), p.3844-3855

2013

Volltextzugriff (PDF)

1 – 25 von 439

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(315)
Mit Volltextzugriff
(430)

Publikationsform

Sprache

Englisch
(439)
Japanisch
(43)

Erscheinungsjahr

n.n

Thema

Science & Technology
(203)
Life Sciences & Biomedicine
(200)
Humans
(182)
Hematology
(141)
Transplantation
(94)
Male
(92)
Female
(91)
Immunology
(89)
Adult
(79)
Child
(71)
Adolescent
(68)
Middle Aged
(61)
Hematology, Oncology And Palliative Medicine
(58)
Young Adult
(54)
Oncology
(51)
Child, Preschool
(49)
Hematopoietic Stem Cell Transplantation
(44)
Aged
(40)
Infant
(37)
Killer Cells, Natural - Immunology
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Can allogeneic haematopoietic cell transplantation be curative in classical Crohn's disease?

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

Clinical utility of natural killer cells in cancer therapy and transplantation

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood

Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer

Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT)

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

Therapeutic manipulation of innate lymphoid cells

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units

Natural killer–cell differentiation by myeloid progenitors

Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition

Suchergebnisse filtern